In the early therapeutic intervention trial, the therapeutic efficacy of C21 was comparable to the TNF-alpha antagonist etanercept, which is frequently used as potent biological agent in RA patients with insufficient response to conventional disease modifying drugs such as methotrexate (41). This evidence concerns the gene TNF and rheumatoid arthritis.